GGrantIndex
Sort

130,381 grants matching hiv

Role of proviral loci in HIV latency

$833,533
James Ivan Mullins · University Of Washington · R01 · FY2019 · AI

MAPs for Peds: Development of a Microarray Patch for Delivery of Long-Acting Antiretrovirals for Treatment of Pediatric HIV Infection

$833,526
Darin Zehrung · Path · R61 · FY2020 · AI

Therapeutics Targeting Macrophages/Microglia to Eradicate CNS HIV-1 Reservoirs

$833,525
Raymond F. Schinazi · Emory University · R01 · FY2016 · MH

Identification of the Initial Targets of Transmission

$833,492
Thomas Hope · Northwestern University At Chicago · R37 · FY2017 · AI

Donor-specific anti-HIV/SIV immunity mediated by APOBEC3 enzymes

$833,457
Diako Ebrahimi · Texas Biomedical Research Institute · R56 · FY2023 · AI

Core 1: Expression and Molecular Biology (EMB) Core

$833,454
Priscilla K Cooper · University Of Calif-Lawrenc Berkeley Lab · P01 · FY2016 · CA

Strategies for inducing bnAbs against QNES by infection with SHIVs

$833,435
Shiu-Lok Hu · Univ Of Med/Dent Of Nj-Nj Medical School · P01 · FY2011 · AI

In vivo transformation of chimeric antigen receptor B cells for a functional cure of HIV

$833,420
Michael R. Farzan · Boston Children'S Hospital · R01 · FY2025 · AI

Host specific responses in SIV-induced hematosuppression

$833,393
Emory University · R01 · FY2004 · HL

Exploratory human trials of rectal microbicides

$833,379
Anne-Marie Corner · University Of California Los Angeles · U19 · FY2008 · AI

The Cooperative Re-Engagement Controlled Trial (CoRECT

$833,334
Alfred Demaria · Massachusetts State Dept Of Pub Health · U01 · FY2016 · PS

The Cooperative Re-Engagement Controlled Trial (CoRECT)

$833,333
Heidi Jenkins · Connecticut State Dept Of Public Health · U01 · FY2016 · PS

Philadelphia Cooperative Agreement Re-engagement Controlled Trial

$833,333
Kathleen A Brady · Philadelphia Departmentof Public Health · U01 · FY2016 · PS

Arterial Inflammation and Coronary Microvascular Dysfunction among Women with HIV: Missing Pieces to the MI Risk Puzzle

$833,297
Markella V. Zanni · Massachusetts General Hospital · R01 · FY2022 · HL

Arterial Inflammation and Coronary Microvascular Dysfunction among Women with HIV: Missing Pieces to the MI Risk Puzzle

$833,296
Markella V. Zanni · Massachusetts General Hospital · R01 · FY2020 · HL

Arterial Inflammation and Coronary Microvascular Dysfunction among Women with HIV: Missing Pieces to the MI Risk Puzzle

$833,296
Markella V. Zanni · Massachusetts General Hospital · R01 · FY2021 · HL

Molecular and Clinical Studies of Insulin Resistance

$833,192
Rebecca Brown · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2025 · DK

Development of a Sustained Release Injectable Formulation for Long-Term Delivery of ELQs

$833,189
Michael Kevin Riscoe · Oregon Health & Science University · R01 · FY2019 · AI

Structural study of the HIV1 gp41 coat protein

$833,178
Ad Bax · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2015 · DK

Chemoprophylaxis and HIV-Host Interactions

$833,172
Robert M. Grant · J. David Gladstone Institutes · R01 · FY2010 · AI

Blocking type I interferon signaling to reverse T cell exhaustion and control HIV-1 reservoirs

$833,168
Lishan Su · University Of Maryland Baltimore · R01 · FY2021 · AI

EPITOPE BASED DNA VACCINES FOR AIDS THERAPY

$833,081
Idm Pharma, Inc. · P01 · FY2000 · AI

Development of Small-Molecule HIV Entry Inhibitors

$833,040
Progenics Pharmaceuticals, Inc. · R44 · FY2005 · GM

Resubmission: Multilevel Strategies & Tailored HIV Prevention & Care for Young Couples who use Alcohol & Other Drugs Across Cape Town

$833,027
Felicia Amira Browne · Research Triangle Institute · R01 · FY2024 · DA

On-site, high-fidelity target sequencing and absolute quantitation for HIV-1 surveillance

$833,025
Sanggu Kim · Ohio State University · R01 · FY2021 · HG